Welcome to the New Era of Cell Therapy

The new era of cell therapy has well and truly arrived, with the iPSC field holding the power to set a trailblazing fire to the field as recent advances in reprogramming and differentiation have unveiled the potential to develop fully scalable, off-the-shelf cell lines which could reduce cost of goods and increase accessibility to patients.

Join the iPSC-Derived Cell Therapies Summit, across 3 days of carefully curated sessions, as we gather with over 80 of the leading c-level executives and KOLs trailblazing iPSC cell therapies including experts from pre-clinical studies, clinical translation and early process development to landscape the clinical progression, outline GMP compliant processes for scale up, and share strategies to ensure consistency in starting material.

 

Key discussions you can’t afford to miss:

Gain insight into the strategic decision making of Adaptimmune, Kite Pharma, Notch Therapeutics & Cytovia. Ask your questions to uncover iPSCs have become a priority cell starting source and their future plans for portfolio growth
Explore the latest clinical trial case studies to show true safety, efficacy and securing regulatory approval for an iPSC derived product with Cynata & NIH
Optimize differentiation protocols and drive cell purity to unveil the full potential of iPSCs with Stemson Therapeutics, HeartSeed & Umojja Biopharma
Supercharge genetic engineering of iPSC products for enhanced efficacy and potency with Shoreline Bioscience & Exacis

 

Who Attends

Audience composition - iPSC Summit
Seniority - iPSC Summit

"Novel therapeutics are urgently needed and iPSC sourcing provides a uniquely valuable platform on which to design and develop new cancer therapeutics. Sharing and understanding the technologic advances, challenges, and strategies will allow for improved investments and approaches"
Stanley Frankel, CMO, Cytovia Therapeutics